HD-tDCS as a Treatment for Chronic Tinnitus

Sponsor
University Hospital, Antwerp (Other)
Overall Status
Completed
CT.gov ID
NCT04565132
Collaborator
Universiteit Antwerpen (Other)
117
1
29.6

Study Details

Study Description

Brief Summary

Transcranial Direct Current Stimulation (tDCS) aims to induce cortical plasticity by modulating the activity of brain structures. The broad stimulation pattern, which is one of the main limitations of tDCS, can be overcome with the recently developed technique called High-Definition tDCS (HD-TDCS). The objective of the current study is to investigate the effect of HD-tDCS on tinnitus in a large patient cohort.

Condition or Disease Intervention/Treatment Phase
  • Device: High Definition transcranial Direct Current Stimulation
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
117 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Chronic Tinnitus: Outcomes From a Prospective Longitudinal Large Cohort Study
Actual Study Start Date :
Oct 21, 2016
Actual Primary Completion Date :
Apr 8, 2019
Actual Study Completion Date :
Apr 9, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: HD-tDCS

Each patient received a total of six sessions of anodal HD-tDCS of right DLPFC.

Device: High Definition transcranial Direct Current Stimulation
1x1 tDCS low-intensity stimulator and 4x1 multichannel stimulation adaptor (Soterix Medical Inc, New York, NY)

Outcome Measures

Primary Outcome Measures

  1. Change in Tinnitus Functional Index (TFI) [Baseline (before intervention), immediately post intervention, 7 weeks follow-up]

    Tinnitus severity self-report questionnaire, ranging from 0-100 with a higher score representing a more severe tinnitus

Secondary Outcome Measures

  1. Change in Visual Analogue scale (VAS) for tinnitus loudness [Baseline (before intervention), immediately post intervention, 7 weeks follow-up]

    Visual analogue scale measuring tinnitus loudness from 0-100, with a higher score representing a louder tinnitus Visual analogue scale measuring tinnitus loudness from 0-100, with a higher score representing a louder tinnitus

  2. Change in Hospital Anxiety and Depression Scale (HADS) [Baseline (before intervention), immediately post intervention, 7 weeks follow-up]

    Self-report questionnaire concerning anxiety and depression symptoms, ranging from 0-21 for each subscale. A result greater than 8 suggests the presence of a depression and/or anxiety disorder. Visual analogue scale measuring tinnitus loudness from 0-100, with a higher score representing a louder tinnitus

  3. Change in Tinnitus Questionnaire (TQ) [Baseline (before intervention), immediately post intervention, 7 weeks follow-up]

    Tinnitus severity self-report questionnaire, ranging from 0-84 with a higher score representing a more distressing tinnitus

  4. Change in Hyperacusis Questionnaire (HQ) [Baseline (before intervention), immediately post intervention, 7 weeks follow-up]

    Hyperacusis severity self-report questionnaire, ranging from 0-42 with a higher score representing a higher sensitivity to sounds. A score of 28 is the cut-off for auditory hypersensitivity.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • chronic, subjective, non-pulsatile tinnitus

  • met the criteria for HD-tDCS safety

Exclusion Criteria:
  • a middle ear pathology

  • another tinnitus treatment ongoing

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Hospital, Antwerp
  • Universiteit Antwerpen

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University Hospital, Antwerp
ClinicalTrials.gov Identifier:
NCT04565132
Other Study ID Numbers:
  • HDtDCS_extensive
First Posted:
Sep 25, 2020
Last Update Posted:
Sep 25, 2020
Last Verified:
Aug 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Antwerp
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 25, 2020